ASCO: Targeted therapy combo nearly doubles time without disease progression for patients with advanced colorectal cancer
Cohort 3 of the BREAKWATER trial evaluated encorafenib plus cetuximab with FOLFIRI chemotherapy
Updated results demonstrate improved progression‑free survival, better overall survival and consistent side effects with earlier analyses
Findings build on earlier data showing improved responses and survival outcomes
In February, the FDA approved the BREAKWATER regimen with FOLFIRI as a first‑line option for BRAF V600E-mutant metastatic...
ASCO: Tile-based radiation therapy lowers risk of recurrence in brain metastases
A type of radiation treatment implanted during surgery significantly lowers risk of recurrence and may help patients with brain metastases live...
ASCO: Targeted drug outperforms chemotherapy for patients with hard-to-treat lung cancer
Sunvozertinib is an oral pill targeting specific forms of mutant EGFR, made by Dizal Pharmaceutical
Phase 3 WU-KONG28 trial evaluated...
AI-powered atlas reveals new insights into tertiary lymphoid structures as prognostic and response biomarkers in cancer
New spatial atlas of immune cell structures, called tertiary lymphoid structures (TLSs), reveals how key features vary across tumor types and influence patient outcomes Researchers developed scalable AI frameworks to detect, profile and classify these structures from spatial multi-omics data and routine pathology slides Composite scoring approach outperformed conventional TLS measures in stratifying patients by prognosis and...
Direct-to-consumer pharmacies may lower costs for generic prescriptions
Study compared direct purchase prices from Mark Cuban Cost Plus Drug Company to cost-sharing under employer-sponsored insurance
Researchers...
ASCO: UT MD Anderson spotlights emerging precision therapies for rare and difficult-to-treat cancers
ABSTRACTS: 8510, 8008, 6009, 4520
Researchers at The University of Texas MD Anderson Cancer Center will present new findings at the...
Researchers identify drivers of resistance to KRAS inhibitors in colorectal cancer
Colorectal cancer can resist KRAS inhibitors in both genetic and non-genetic ways
An early inflammation surge within days of treatment helps...
Study identifies new marker to find patients with advanced prostate cancer more likely to benefit from combination immunotherapy
Patients with metastatic castration-resistant prostate cancer who do not benefit from chemotherapy need more effective treatment options
Phase...
Tumor microenvironment features may predict immunotherapy response in rare cancers
Phase 2 trial investigated the effectiveness of pembrolizumab (Keytruda) in rare cancers
Overall responses were modest, but analysis showed...
ESTRO: ctDNA improves treatment monitoring for patients receiving metastasis-directed therapy
Analysis from the Phase 2 EXTEND trial showed ctDNA testing provided new insights into treatment response for patients receiving metastasis-directed...
ESTRO: Select breast cancer patients may be able to omit surgery following ablative radiation
Patients in this trial eligible to avoid surgery had a disease control rate of 100% at a median follow-up of over three years ...
New marker aids diagnosis for aggressive prostate cancer
Aggressive prostate cancers often lose expression of traditional markers after treatment, making it hard to diagnose the tumor’s origin and...
Study may help predict response to chemotherapy in triple-negative breast cancer
Triple-negative breast cancer is treated with chemotherapy, but outcomes vary significantly among patients
Tumors have unique characteristics...
Low-intensity combination therapy yields strong outcomes in hard-to-treat AML
Researchers combined an alternating regimen of lower-intensity therapy with a targeted agent in older or medically fragile patients with newly...
RAS inhibitor daraxonrasib demonstrates initial anti-tumor activity in pancreatic cancer
Daraxonrasib is an oral, multi-selective RAS inhibitor from Revolution Medicines
Data from this trial previously prompted the Food and Drug...
Scientists find blood-based biomarkers for inflammatory breast cancer
Inflammatory breast cancer (IBC) is highly aggressive, but there are no known genomic differences that can tell it apart from other breast cancers...
Researchers find biomarker of chemotherapy resistance in relapsed lung cancer
Standard chemotherapy treatment for small cell lung cancer (SCLC) often leads to resistance and eventual relapse
The YAP1 protein emerges in...
Tumor markers in rare appendiceal cancer may predict treatment outcomes
Researchers monitored levels of common blood markers before and after surgery to remove cancer
Study found...
Researchers find potential one-two punch against triple-negative breast cancer
Many breast cancer therapies work by causing DNA replication stress, but triple-negative breast cancer (TNBC) cells survive this stress, even...